Skip to main content
Equibles

Alyeska Investment Group, L.P.

Position in ALGS — Aligos Therapeutics, Inc.

CIK 1453072 CHICAGO, IL
Back to ALGS Full portfolio

Position in ALGS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$2,377,240
-$683,920 QoQ
Shares Held
412,000
0.0% QoQ
Ownership
11.5%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#2
of 31 holders
Holding Since
Dec 2020
11 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ALGS Over Time

Shares Held

Position Value (USD)

Derivatives in ALGS

reported options exposure · as of Mar 31, 2024
CallValue
$5,981,152
CallShares
244,129
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Alyeska Investment Group, L.P. holds $989,063,778 across 83 Biotechnology names. ALGS ranks #64 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 659,279 $123,469,771
2 IONS
Ionis Pharmaceuticals Inc
 1,417,916 $112,426,559
3 PTGX
Protagonist Therapeutics, Inc
 889,298 $109,010,148
4 XENE
Xenon Pharmaceuticals Inc.
 697,692 $42,112,689
5 MRNA
Moderna, Inc.
 560,819 $39,274,154
6 KYMR
Kymera Therapeutics, Inc.
 276,455 $31,701,094
7 LBRX
Lb Pharmaceuticals Inc
 863,947 $28,039,399
8 PRAX
Praxis Precision Medicines, Inc.
 80,846 $27,066,432

All Filings in ALGS

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,377,240 412,000
2026-03-31 $3,061,160 412,000
2025-12-31 $3,839,840 412,000
2025-09-30 $4,037,600 412,000
2025-06-30 $2,970,520 412,000
2025-03-31 $3,399,000 412,000
2024-06-30 $99,481 284,233
2024-03-31 $5,981,152 6,103,217
2023-12-31 $1,913,791 2,882,216
2023-12-31 $4,052,536 6,103,217
2021-03-31 $341,100 15,000
2020-12-31 $414,750 15,000